scholarly journals Celiac disease‐associated Neisseria flavescens decreases mitochondrial respiration in CaCo‐2 epithelial cells: Impact of Lactobacillus paracasei CBA L74 on bacterial‐induced cellular imbalance

2019 ◽  
Vol 21 (8) ◽  
Author(s):  
Giuseppe Labruna ◽  
Merlin Nanayakkara ◽  
Chiara Pagliuca ◽  
Marcella Nunziato ◽  
Laura Iaffaldano ◽  
...  
Author(s):  
Hoora Shaghaghi ◽  
Rachel Para ◽  
Cara Tran ◽  
Jesse Roman ◽  
Yemaiza Ojeda-Lassalle ◽  
...  

Cells ◽  
2020 ◽  
Vol 9 (2) ◽  
pp. 516
Author(s):  
Agnieszka Sowińska ◽  
Yasser Morsy ◽  
Elżbieta Czarnowska ◽  
Beata Oralewska ◽  
Ewa Konopka ◽  
...  

Disruption of epithelial junctional complex (EJC), especially tight junctions (TJ), resulting in increased intestinal permeability, is supposed to activate the enhanced immune response to gluten and to induce the development of celiac disease (CD). This study is aimed to present the role of EJC in CD pathogenesis. To analyze differentially expressed genes the next-generation mRNA sequencing data from CD326+ epithelial cells isolated from non-celiac and celiac patients were involved. Ultrastructural studies with morphometry of EJC were done in potential CD, newly recognized active CD, and non-celiac controls. The transcriptional analysis suggested disturbances of epithelium and the most significant gene ontology enriched terms in epithelial cells from CD patients related to the plasma membrane, extracellular exome, extracellular region, and extracellular space. Ultrastructural analyses showed significantly tighter TJ, anomalies in desmosomes, dilatations of intercellular space, and shorter microvilli in potential and active CD compared to controls. Enterocytes of fetal-like type and significantly wider adherence junctions were observed only in active CD. In conclusion, the results do not support the hypothesis that an increased passage of gluten peptides by unsealing TJ precedes CD development. However, increased intestinal permeability due to abnormality of epithelium might play a role in CD onset.


PLoS ONE ◽  
2017 ◽  
Vol 12 (9) ◽  
pp. e0185025 ◽  
Author(s):  
Grzegorz Pietz ◽  
Rituparna De ◽  
Maria Hedberg ◽  
Veronika Sjöberg ◽  
Olof Sandström ◽  
...  

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 3899-3899
Author(s):  
Michele Spina ◽  
Vallì De Re ◽  
Maria Paola Simula ◽  
Laura Caggiari ◽  
Nicoletta Orzes ◽  
...  

Abstract Celiac disease is induced by gliadin in genetically susceptible individuals expressing HLA-DQ2 or HLA-DQ8. The mechanisms underlying the expansion of interferon g-producing intraepithelial cytotoxic T lymphocytes (CTLs) and the destruction of the epithelial cells (EC) lining the small intestine of celiac patients have remained elusive. Intraepithelial lymphocytes (IELs) can undergo malignant transformation during the course of rare but severe complications of celiac disease: enteropathy associated T-cell lymphomas and refractory sprue. These complications support the idea that celiac disease IELs are permanently submitted to stimuli that promote their expansion and ultimately may favour their transformation. Altogether, these observations underline the importance of understanding the mechanism(s) that drives the expansion of IELs and their role in the pathogenesis of the epithelial lesions. A model enhanced presentation of gliadin peptides by DQ2 or DQ8 molecules to CD4 + cells in the lamina propria which results in secretion of interferon gamma and other cytokines that may be deleterious to gut epithelial cells, however gluten-specific IE-CTL could not be identified. To characterize T cells and protein expression in CD patients in relationship to severe complications, we used for the first time 2D-Dige approaches with well-characterized CD-associated gut biopsies. Fourteen adult patients diagnosed as CD were studied. All patients were characterized for the presence of anti-transglutaminase antibodies, VDJ-TcR and VDJ-BcR genescan pattern, HLA DQ and KIRs/ligand genotypes, villous atrophy, and to clinical response to gluten-free diet (13 out of 14 cases). One of these patients presented a restricted T cell population both in the peripheral blood as well as in the gut biopsy. Another patient presented a concomitant DLCL lymphoma. 2 further patients, with biopsies for intestinal disorders but with HLA-DQ2 and DQ8 negative, were used as controls. Patient with the T cell restriction pattern showed a prevalent Tg clone in peripheral blood and two identical over-expanded Tg clones in the peripheral blood a nd gut biopsy. Moreover in the gut biopsy it was also present a restricted Tb clone. Sequences from these 4 clones were reported in the EMBL database. HLA DQ2+D8 is found only in the case of CD-DLCL associated, 5 cases were DQ2 homozigote, 6 cases were DQ2 heterozygote (including the case with the restricted TCR pattern), 2 cases have neither DQ2 nor DQ8 heterodimer. A complete set of KIR with activating function (KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS5 KIR3DS1) was present only in two samples, one of them with the T cell restricted pattern. Data from comparative protein expression obtained by 2D-Dige analysis, are in course. Although the number of control individuals and patients analysed were still low, the frequency of KIR with activating function was found to be higher in patients, particularly in sprue CD with T cell restriction, than in controls. This indicates that genotypic profiles of NK-T-CD patients may be characterized by an increased presence of activating KIRs.


2018 ◽  
Vol 2 (S1) ◽  
pp. 34-34
Author(s):  
Sara Maimouni ◽  
Mi-Hye Lee ◽  
You-Me Sung ◽  
Chokri Ouaari ◽  
Stephen Byers

OBJECTIVES/SPECIFIC AIMS: One of the driving mechanisms of cancer progression is the reprogramming of metabolic pathways in intermediary metabolism. Cancers increase their energy expenditure by increasing ATP production for utilization in anabolic pathways to increase production of proteins, nucleic acids and lipids. The Warburg effect, where cancer cells predominantly use aerobic glycolysis rather than oxidative phosphorylation to produce ATP, was long thought to be the main initiating pathway in increasing tumor burden. However, compelling new evidence shows that there exists metabolic heterogeneity among and within tumors. Mitochondrial respiration often plays a major role in tumor progression, as many different cancers contain a subpopulation of slow-cycling tumor-initiating cells that are multidrug-resistant and dependent on oxidative phosphorylation. These cells represent a target for cancer therapy. In this study, we identification a novel endogenous regulator of mitochondrial respiration, retinoic acid receptor responder 1 (RARRES1). METHODS/STUDY POPULATION: We assessed the metabolic phenotype of RARRES1-depleted normal epithelial cells through metabolomics, a flux analyzer and blotting for phosphorylation of AMP kinase, a major regulator of energy homeostasis. We further examined mitochondrial energetics by staining the mitochondria with TMRM and Mito-Tracker. We then analyzed the apoptotic phenotype of epithelial cells with depletion of RARRES1 with fluorescence-activated cell sorting analysis of annexin V-staining. RESULTS/ANTICIPATED RESULTS: Remarkably, fluorescence-activated cell sorting analysis of annexin V-stained epithelial cells with depletion of RARRES1 were resistant to all studied modes of cell death, implying an effect on a fundamental cell process. By using proteomics, metabolomics, cellular and molecular analyses, our data show that RARRES1 regulates mitochondrial membrane potential and subsequently alters 1-carbon metabolism by modulating the function of the mitochondrial voltage-dependent anion channel. We believe this is the first example of a tumor suppressor protein that functions to directly regulate mitochondrial energetics. Using an extracellular flux analyzer, our data also show that depletion of RARRES1 causes an increase in mitochondrial respiration and ATP production, thus enhancing biosynthetic pathways that drive the pathogenicity and survival of cancer. The metabolic and anti-apoptotic phenotype of RARRES1-depleted cells was reversed by treatment of metformin, a mitochondrial inhibitor. DISCUSSION/SIGNIFICANCE OF IMPACT: These data lay the foundation for metabo-therapy of the many tumor types that exhibit RARRES1 depletion and may have the added benefit of targeting drug-resistant tumor-initiating cells.


Author(s):  
Ying Yang ◽  
Chensheng Li ◽  
Xia Gu ◽  
Junhui Zhen ◽  
Suwei Zhu ◽  
...  

Mitochondrial injury of tubular epithelial cells (TECs) is the key pathogenic event underlying various kidney diseases and a potential intervening target as well. Our previous study demonstrated that ING2 is ubiquitously expressed at tubulointerstitial area within kidneys, while its role in regulating TEC mitochondrial respiration is not fully elucidated. To clarify the roles of ING2 in mitochondrial homeostasis of TECs and pathogenesis of acute ischemic kidney injury, Western blot, PCR, immunofluorescence, immunoprecipitation, and oxygen consumption rate assay were applied to address the roles of ING2 in modulating mitochondrial respiration. We further complemented these studies with acute ischemic kidney injury both in vitro and in vivo. In vitro study demonstrated ING2 could positively control TEC mitochondrial respiration. Concurrently, both mRNA and protein levels of mtDNA encoded respiratory chain components were altered by ING2, suggesting ING2 could regulate mtDNA transcription. In mechanism, ING2 could regulate the ubiquitination of a newly identified mitochondrial transcription factor MRPL12, thereby modulating its cellular stability and abundance. We also demonstrated ING2-mediated modulation on mtDNA transcription and mitochondrial respiration are involved in serum deprivation induced TEC injuries. Finally, immunohistochemistry study revealed that ING2 expression was significantly altered in kidney biopsies with acute ischemic kidney injury. In vivo study suggested that kidney specific ING2 overexpression could effectively ameliorate acute ischemic kidney injury. Our study demonstrated that ING2 is a crucial modulator of TEC mitochondrial respiration. These findings suggested a unrecognized role of ING2 in TEC mitochondrial energetic homeostasis and a potential intervening target for TEC mitochondrial injury associated pathologies.


Human Cell ◽  
2017 ◽  
Vol 30 (4) ◽  
pp. 258-266 ◽  
Author(s):  
Shiro Takeda ◽  
Keiji Igoshi ◽  
Chuluunbat Tsend-Ayush ◽  
Tsendesuren Oyunsuren ◽  
Ryoichi Sakata ◽  
...  

2011 ◽  
Vol 30 (4) ◽  
pp. 541-546 ◽  
Author(s):  
Olimpia Vincentini ◽  
Maria Giovanna Quaranta ◽  
Marina Viora ◽  
Carlo Agostoni ◽  
Marco Silano

2017 ◽  
Vol 1 (S1) ◽  
pp. 9-10
Author(s):  
Sara Maimouni ◽  
Mi-Hye Lee ◽  
Stephen Byers

OBJECTIVES/SPECIFIC AIMS: The goal of this study is to examine bioenergetic phenotype of retinoic acid receptor responder 1 (RARRES1)-depleted epithelial cells and to facilitate the discovery of personalized metabo-therapeutics in the context of cancers characterized with loss of or low expression of RARRES1. METHODS/STUDY POPULATION: Anoikis assay and annexinV labeling were used to assess drug resistance and apoptotic phenotype in RARRES1-depleted epithelial cells. Metabolomics, AMP kinase activity, mito-tracker, and extracellular flux assays were used to examine the bioenergetic profile of RARRES1-depleted epithelial cells. Extracellular flux assays were used to assess the phenotype of RARRES1-depleted epithelial cells treated with or without metformin. RESULTS/ANTICIPATED RESULTS: RARRES1 is a major regulator of mitochondrial function. Its depletion in tumors induces an oxidative phosphorylation dependent phenotype and subsequently increases ATP abundance in the cell, enhances anabolic pathways and increases survival. Treatment with FDA approved mitochondrial respiration inhibitor, metformin, reversed the metabolic phenotype of RARRES1 depleted-epithelial cells. Metformin could be the ideal therapeutics to reduce tumor burden in cancers with loss of or low expression of RARRES1. DISCUSSION/SIGNIFICANCE OF IMPACT: Bioenergetic dynamics are emerging as a basis for understanding the pathology of cancer. The malignancy progresses as its metabolic pattern and mitochondrial respiration become more dysfunctional. The regulatory pathways of bioenergetic dynamics are currently poorly understood, and the characterization of proteins implicated in those processes must be assessed. One understudied protein and tumor suppressor is RARRES1. RARRES1 is induced by retinoic acid (a major metabolic regulator) and functions as a putative carboxypeptidase inhibitor. Understanding the connection between this carboxypeptidase inhibitor and intermediary metabolism will enlighten our understanding of the bioenergetic profile of cells and facilitate the discovery of personalized metabo-therapeutics in the context of cancer.


Sign in / Sign up

Export Citation Format

Share Document